the study will discuss different pattern of treatment and the outcomes of locally advanced rectal carcinoma as a retrospective study.
The study will be conducted at Department of Clinical Oncology, Sohag University Hospital and Sohag Cancer center, Sohag, Egypt.
including patients diagnosed and treated between 2018 and 2025. and the data will be collected from reports .

Start Date01 Mar 2026

Sponsor / Collaborator

Sohag University

ChiCTR2600122927

/ Not yet recruitingNot Applicable

Evaluation of the Effectiveness and Strategy Optimization of a New Individualized Diagnosis and Treatment Plan for Type 2 Diabetes Mellitus: A National Multicenter RCT Study - Evaluation of the Effectiveness of an Auxiliary Decision Support System Combined with the Long-Acting DPP-4 Enzyme Inhibitor Cofrogliptin in MARD Type

Start Date07 Feb 2026

Sponsor / Collaborator

Beijing Hospital of the Ministry of Health

100 Clinical Results associated with Saxagliptin Hydrate

100 Translational Medicine associated with Saxagliptin Hydrate

100 Patents (Medical) associated with Saxagliptin Hydrate

1,092

Literatures (Medical) associated with Saxagliptin Hydrate

01 Jul 2026·DIABETES OBESITY & METABOLISM

Drug‐Associated Ketoacidosis: A Comprehensive Disproportionality Analysis Based on the FAERS Database

Article

Author: Chen, Xiaoyu ; Xu, Yinpeng ; Gao, Hongli ; Zhou, Yujie ; Du, Pengqiang

ABSTRACT:

Objective:

Ketoacidosis is a critical adverse event requiring close clinical monitoring. Based on the Adverse Event Reporting System (FAERS) database of the U.S. Food and Drug Administration (FDA), this study aimed to identify the drugs with the closest association and the highest signal strength with the risk of drug‐induced ketoacidosis by performing disproportionality analysis, thereby providing a reference for clinical medication safety.

Methods:

Adverse event data from the first quarter of 2004 to the second quarter of 2025 were retrieved from the FAERS database. Preferred Terms (PTs) related to ‘ketoacidosis’ in the Medical Dictionary for Regulatory Activities (MedDRA) were used as outcome indicators. The generic names of drugs were standardized with reference to the DrugBank database. Disproportionality analysis was conducted using the Reporting Odds Ratio (ROR), Proportional Reporting Ratio (PRR) and Information Component (IC) of Bayesian Confidence Propagation Neural Network and the time trend of drug‐induced ketoacidosis was analysed by combining the Time‐to‐Onset (TTO) analysis.

Results:

A total of 22 375 298 adverse event reports were included in this study, among which 6977 were related to ketoacidosis. The top 5 drugs with the highest number of reports were metformin, quetiapine, empagliflozin, canagliflozin and dapagliflozin in sequence; whereas the top 5 drugs with the highest ROR values were dapagliflozin, dapagliflozin‐saxagliptin, ipragliflozin, ertugliflozin‐sitagliptin and empagliflozin. Among the top 50 drugs ranked by ROR, 36 (72%) had no mention of ketoacidosis risk in their package inserts. TTO analysis showed that the incidence frequency of ketoacidosis induced by quetiapine, olanzapine, aripiprazole, pembrolizumab, empagliflozin/linagliptin and nivolumab remained stable with the duration of medication; the incidence frequency induced by tirzepatide and alpelisib increased gradually over time; while that induced by empagliflozin, canagliflozin and other drugs decreased gradually with time.

Conclusion:

The high‐risk drugs for inducing ketoacidosis are mainly sodium‐glucose cotransporter 2 (SGLT2) inhibitors (e.g., dapagliflozin and empagliflozin), followed by psychotropic drugs (e.g., quetiapine). Attention should also be paid to the potential risk of ketoacidosis induced by some drugs that do not mention this adverse reaction in their package inserts. The findings of this study can provide data support for clinical medication monitoring and the revision of drug package inserts.

12 Jun 2026·ACS Pharmacology & Translational Science

Phosphatidylinositol-3-kinase/Protein Kinase B (PI3K/AKT) and Nucleotide-Binding Oligomerization Domain-like Receptor Family Pyrin Domain Containing 3 (NLRP3) Inflammasome Modulation Underlies the Neuroprotective Effects of Vildagliptin in a Rotenone-Induced Mouse Model of Parkinson’s Disease

Article

Author: Patel, Dishank ; Shah, Jigna ; Roy, Sudeep ; Soni, Ritu ; Bhogal, Inderjeet

Parkinson's disease (PD) is a chronic neurodegenerative disorder marked by the gradual loss of dopaminergic neurons. Mitochondrial impairment, neuroinflammation, oxidative stress, and abnormal aggregation of α-synuclein are the most prominent features of the pathology. Current therapeutic approaches lack disease-modifying abilities and render only symptomatic relief. It has been observed that increased risk of PD is somehow linked to type 2 diabetes mellitus, and these pathologies share some common signaling cascades. Hence, repurposing hypoglycemic agents targeting specific molecular signaling pathways that mediate α-synuclein aggregation and neuroinflammation can be an effective disease-modifying strategy for PD treatment. This study investigated the neuroprotective potential of the DPP-4 inhibitor, vildagliptin, in a mouse model of chemically induced PD. In silico analyses, including molecular docking as well as molecular dynamics simulation, demonstrate good binding affinity as well as stable interaction of vildagliptin with PI3K (4YKN) and NLRP3 (7ALV) proteins in comparison to other DPP-4 inhibitors (sitagliptin, saxagliptin, linagliptin, and alogliptin). In in vivo studies, it was observed that vildagliptin improved motor coordination, muscle strength, and cognitive abilities. Biochemical assays show a reduction in MDA and restoration of GSH, indicating alleviation of oxidative stress. Moreover, at the molecular level, vildagliptin upregulated neuroprotective markers like PI3K, AKT, CREB, BDNF, and TH and downregulated pathological and inflammatory markers like NLRP3, IL-1β, caspase-1, gasdermin D, and α-syn. Histopathological and immunohistochemistry studies also demonstrate preservation of dopaminergic neurons. These findings collectively suggest that vildagliptin rendered neuroprotection by PI3K/AKT activation and inhibition of NLRP3-mediated neuroinflammation and apoptosis. In conclusion, we can say that vildagliptin possesses definitive neuroprotective potential as a disease-modifying therapy that warrants further clinical exploration.

01 Jun 2026·EUROPEAN JOURNAL OF PHARMACOLOGY

Design, synthesis, and inhibition of oxidative, amyloidogenic, and cholinergic dysfunction of saxagliptin-derived schiff bases against STZ-induced sporadic AD-like pathology

Article

Author: Pakeeraiah, Kakarla ; Prusty, Shakti Ketan ; Pattanaik, Swagata ; Lopamudra ; Paidesetty, Sudhir Kumar ; Sahu, Pratap Kumar ; Panda, Preetesh Kumar

Alzheimer's disease (AD) shares significant pathological convergence with diabetes, primarily through insulin resistance. This leads to oxidative stress, neuronal inflammation, plaque formation, cholinergic dysfunction, and impaired neuronal survival. Herein, we report 10 Saxagliptin (SXG, a potent DPP-IV inhibitor)-derived Schiff base derivatives that were virtually designed and screened. Five leads were prioritized using ADMET profiling and molecular docking, then synthesized via Schiff base condensation with selected aryl aldehydes to target AD progression associated with diabetes. Structural integrity, redox activity, and stability were confirmed by comprehensive characterization, including chromatographic and spectroscopic analyses, DFT calculations, and in vitro antioxidant assays. Neuroprotective potential was thus assessed in vivo by inducing AD-like pathology in rats with a single i.p. dose of STZ at 45 mg/kg, thereby reproducing brain insulin resistance, oxidative-nitrosative stress, and cholinergic dysfunction. Significant neurodegeneration in STZ-treated rats was evidenced by behavioral analyses, biochemical markers (AChE, Aβ42), oxidative stress indices (SOD, CAT, GSH, GPx, MDA, NO, MPO), and hippocampal histology. Treatment with SXG and derivatives at 0.5 mg/kg, orally, resulted in significant restoration of antioxidant defenses, inhibition of lipid peroxidation and NO overproduction, reduction of inflammatory oxidative bursts, and improved cognition in treated groups. Remarkably, derivatives 3c and 3e showed superior free-radical scavenging and greater regulation of redox biomarkers, which were associated with healthy, defined hippocampal cytoarchitecture and reduced neuronal pyknosis and necrosis compared with SXG. Additionally, 3e showed strong therapeutic efficacy by targeting oxidative stress, cholinergic, and amyloidogenic pathways synchronously.

News (Medical) associated with Saxagliptin Hydrate

24 Jul 2026

·www.genohopebio.com

Hair Loss With GLP-1 Drugs Is Rare, But Real, Studies Find

Jul 24, 2026 Leave a message New diagnoses of alopecia are more common with GLP-1 drugs than with other diabetes drugs, although rare overall, two studies suggest New-onset alopecia was more common with tirzepatide than with semaglutide in a third study Weight loss alone likely doesn't explain patients' hair loss, researchers say By Nancy Lapid July 22 (Reuters) - The risk of hair loss in patients taking GLP-1 drugs for obesity or diabetes, while low, is higher than with other diabetes drugs, new studies suggest. At two or more years after starting treatment, the odds of a new diagnosis of alopecia in GLP-1 users were 37% higher than in users of so-called SGLT-2 drugs and 68% higher versus DPP-4 drugs, researchers at the University of Pennsylvania reported on Wednesday in The BMJ. Actual rates of alopecia were low, ranging from roughly 3 to 9 per 1,000 people per year, with between 11,000 and 15,000 people in each drug-class group. GLP-1 drugs in the study included semaglutide, sold by Novo Nordisk as Wegovy and Ozempic; tirzepatide, sold by Eli Lilly ( LLY ) as Zepbound and Mounjaro; and older drugs in the class. SGLT-2 drugs included Johnson & Johnson's ( JNJ ) Invokana, AstraZeneca's ( AZN ) Farxiga, and Jardiance from Boehringer Ingelheim and Eli Lilly ( LLY ). DPP-4 inhibitors included Merck's ( MRK ) Januvia and AstraZeneca's ( AZN ) Onglyza. A separate recent study in the Journal of the American Academy of Dermatology with more than 1 million participants worldwide found significantly higher risks of various subtypes of alopecia with GLP-1 drugs than with the commonly used diabetes drug metformin. A third new study suggests GLP-1 users face higher alopecia odds with tirzepatide than with semaglutide. Researchers at Cambridge, Massachusetts-based analytics firm nference compared 11,046 patients taking tirzepatide with the same number taking semaglutide. Rates of new-onset alopecia were 4.24% with tirzepatide and 3.33% with semaglutide, according to a preprint submitted for peer review. In female users of GLP-1 drugs, those rates were 5.44% with tirzepatide versus 3.63% with semaglutide, the researchers said. All three papers say that hair loss often accompanies weight loss and is often reversible. But in the nference study, the risk was higher with tirzepatide regardless of how much weight patients lost or how much of the drug they received, which suggests that other explanations for hair loss may need to be considered, the researchers said. For example, the study also showed that alopecia was more likely in patients with thyroid disease or other endocrine disorders, which could indicate a connection to baseline hormonal, autoimmune or dermatologic risk factors, said Venky Soundararajan, who led the nference study. "This supports more individualized counseling and surveillance rather than a generic message that weight loss itself inevitably causes hair loss," he said. (Reporting by Nancy Lapid; Editing by Edmund Klamann) GenoHope Biotech Ltd. A leading manufacturer of GLP-1 API Approal by FDA Welcome any Inquiry WhatsApp/Tel:+8613833133635 Email:info@genohopebio.com Send Inquiry

Clinical Result

29 Aug 2025

·www.einpresswire.com

July - September 2021 | Potential Signals of Serious Risks/New Safety Information Identified by the FDA Adverse Event Reporting System (FAERS)

Ajovy (fremanezumab-vfrm) Emgality (galcanezumab-gnlm) Nurtec ODT (rimegepant) Ubrelvy (ubrogepant) Vyepti (eptinezumab-jjmr) Hypertension The "Warnings and Precautions", "Adverse Reactions", "Patient Counseling Information", and "Patient Information" sections of the labeling were updated in March 2025 to include information about the risk of hypertension. Example: Ajovy labeling Apriso (mesalamine) Asacol (mesalamine) Asacol HD (mesalamine) Azulfidine (sulfasalazine) Azulfidine EN-Tabs (sulfasalazine) Canasa (mesalamine) Colazal (balsalazide disodium) Delzicol (mesalamine) Dipentum (osalazine sodium) Giazo (balsalazide disodium) Lialda (mesalamine) Rowasa (mesalamine) Pentasa (mesalamine) Severe cutaneous adverse reactions The Warnings and Precautions section of the labeling was updated November 2021 to include severe cutaneous adverse reactions. Example: Delzicol labeling Avastin (bevacizumab) Mvasi (bevacizumab-awwb) Zirabev (bevacizumab-bvzr) Pancreatitis FDA determined that no action is necessary at the time based on available information. Avastin (bevacizumab) Mvasi (bevacizumab-awwb) Zirabev (bevacizumab-bvzr) Anaphylactic shock The "Warnings and Precautions" section of the labeling was updated between September 2022 and February 2023 to include anaphylactoid/anaphylactic reactions. Example: Avastin labeling Ayvakit (avapritinib) Photosensitivity reaction The "Warnings and Precautions", "Adverse Reactions", "Patient Counseling Information", and "Patient Information" sections of the labeling were updated in March 2023 to include information about photosensitivity. Ayvakit labeling Azacitidine Onureg (azacitidine) Vidaza (azacitidine) Generic products containing azacitidine Pericarditis The "Adverse Reactions" section of the labeling was updated between September 2022 and June 2023 to include pericarditis. Example: Vidaza labeling FDA determined that no action is necessary at the time based on available information for Onureg. Bavencio (avelumab) Imfinzi (durvalumab) Libtayo (cemiplimab-rwlc) Keytruda (pembrolizumab) Opdivo (nivolumab) Tecentriq (atezolizumab) Yervoy (ipilimumab) Tumour lysis syndrome FDA determined that no action is necessary at the time based on available information. Cymbalta (duloxetine hydrochloride) Drizalma Sprinkle (duloxetine hydrochloride) Generic products containing duloxetine hydrochloride Anosmia, Hyposmia This issue is posted as two individual newly identified safety signal (NISS) entries in the January-March 2022 quarter, to reflect the focus on the potential signals of anosmia and hyposmia, separately. Darzalex (daratumumab) Darzalex Faspro (daratumumab and hyaluronidase-fihj) Blood stem cell transplant failure FDA determined that no action is necessary at the time based on available information. Dipeptidyl peptidase-4 (DPP-4) inhibitors Glyxambi (empagliflozin and linagliptin) Janumet (metformin hydrochloride and sitagliptin phosphate) Janumet XR (metformin hydrochloride and sitagliptin phosphate) Jentadueto (linagliptin and metformin hydrochloride) Jentadueto XR (linagliptin and metformin hydrochloride) Kazano (alogliptin and metformin hydrochloride) Kombiglyze XR (metformin hydrochloride and saxagliptin) Nesina (alogliptin) Onglyza (saxagliptin) Oseni (alogliptin and pioglitazone) Steglujan (ertugliflozin and sitagliptin) Tradjenta (linagliptin) Trijardy XR (empagliflozin, linagliptin and metformin hydrochloride) Qtern (saxagliptin and dapagliflozin) Generic products containing dipeptidyl peptidase-4 inhibitors Tubulointerstitial nephritis The "Adverse Reactions" section of the labeling was updated between March 2022 and June 2022 for products containing alogliptin and sitagliptin to include tubulointerstitial nephritis. Example: Janumet labeling FDA determined that no action is necessary for products containing linagliptin and saxagliptin at the time based on available information. *An administrative error resulted in the omission of Januvia from the list of product names after the initial quarterly report was posted. Dupixent (dupilumab) Angioedema The "Warnings and Precautions" and "Adverse Reactions" sections of the labeling were updated in December 2021 to include angioedema. Dupixent labeling Glucagon-like peptide-1 (GLP-1) analogues Adlyxin (lixisenatide) Bydureon (exenatide) Bydureon BCise (exenatide) Byetta (exenatide) Ozempic (semaglutide) Rybelsus (semaglutide) Saxenda (liraglutide) Soliqua 100/33 (insulin glargine and lixisenatide injection) Trulicity (dulaglutide) Victoza (liraglutide) Wegovy (semaglutide) Xultophy 100/3.6 (insulin degludec and liraglutide injection) Generic products containing glucagon-like peptide-1 analogues Gallbladder related disorders The "Warnings and Precautions", "Adverse Reactions", and "Patient Counseling Information" sections of the GLP-1 analogues labeling were updated between March 2022 and June 2022 to include information about acute gallbladder disease. Example: Adlyxin labeling FDA has determined that the last approved labeling for Saxenda and Wegovy is adequately labeled for acute gallbladder disease, and that no further regulatory action is needed at this time. Gonadotropin releasing hormone (GnRH) analogues Fensolvi (leuprolide acetate) Lupron Depot-PED (leuprolide acetate) Supprelin LA (histrelin acetate) Synarel (nafarelin acetate) Triptodur (triptorelin) Idiopathic intracranial hypertension The "Warnings", "Precautions", and "Adverse Reactions" sections of the labeling were updated in April 2022 to include idiopathic intracranial hypertension. Example: Fensolvi labeling Jakafi (ruxolitinib phosphate) Herpes simplex virus (HSV) reactivation and/or disseminated HSV The "Dosage and Administration", "Warnings and Precautions", and "Adverse Reactions" sections of the labeling were updated in January 2023 to include information about herpes simplex and herpes zoster infections. Jakafi labeling Ibrance (palbociclib) Kisqali (ribociclib) Kisqali Femara Co-Pack (letrozole and ribociclib) Embolic and thrombotic events, venous The "Adverse Reactions" section of the Ibrance labeling was updated in December 2024 to include venous thromboembolism. Ibrance labeling FDA determined that no action is necessary at the time for Kisqali and Kisqali Femara Co-Pack based on available information. Ocrevus (ocrelizumab) Myocardial infarction FDA determined that no action is necessary at the time based on available information. Potassium Chloride Product preparation error The “Warnings” section of the labeling was updated in December 2022 to include information about fatal cardiac adverse reactions with intravenous administration of undiluted potassium chloride. Praxbind (idarucizumab) Wrong dose errors The carton labeling and "Dosage and Administration" sections of the labeling were revised in February 2022 to clarify the number of vials included in each carton and the recommended dosing. Praxbind labeling Qbrexza (glycopyrronium tosylate) Accidental exposure to product The container label, carton labeling, "Dosage and Administration", "Warnings and Precautions", "Patient Counseling Information", and "Patient Information" sections of the labeling were updated in October 2022 to include information about accidental exposure. Qbrexza labeling Qbrexza (glycopyrronium tosylate) Urinary retention The “Warnings and Precautions”, “Adverse Reactions”, and “Patient Counseling Information” sections of the labeling were updated in October 2022 to include information about new or worsening urinary retention. Qbrexza labeling Sodium-glucose cotransporter-2 (SGLT-2) inhibitors Farxiga (dapagliflozin) Glyxambi (empagliflozin and linagliptin) Invokamet (canagliflozin and metformin hydrochloride) Invokamet XR (canagliflozin and metformin hydrochloride) Invokana (canagliflozin) Jardiance (empagliflozin) Qtern (saxagliptin and dapagliflozin) Steglatro (ertugliflozin) Steglujan (ertugliflozin and sitagliptin) Segluromet (ertugliflozin and metformin hydrochloride) Synjardy (empagliflozin and metformin hydrochloride) Synjardy XR (empagliflozin and metformin hydrochloride) Trijardy XR (empagliflozin, linagliptin and metformin hydrochloride) Xigduo XR (dapagliflozin and metformin) Generic products containing sodium-glucose cotransporter-2 (SGLT-2) inhibitors Tubulointerstitial nephritis FDA determined that no action is necessary at the time based on available information. Somatostatin Receptor Imaging Agents Detectnet (copper Cu-64 dotatate injection) Gallium Dotatoc (GA 68) Octreoscan (Indium In 111 Pentetreotide) Netspot (Gallium GA 68 Dotatate) Hypersensitivity The "Warnings and Precautions" and "Adverse Reactions" sections of the labeling were updated in December 2021 to include hypersensitivity reactions. Example: Netspot labeling Stromectol (ivermectin) Generic products containing ivermectin Off label use FDA determined that no action is necessary at the time based on available information. Stromectol (ivermectin) Generic products containing ivermectin Neurotoxicity The "Warnings", "Adverse Reactions", and "Overdosage" sections of the labeling were updated in March 2022 to include neurotoxicity. Example: Stromectol labeling Sunosi (solriamfetol hydrochloride) Hypersensitivity FDA determined that no action is necessary at the time based on available information. Vivitrol (naltrexone) Incorrect route of product administration The container label (vial), carton labeling, "Dosage and Administration", "Warnings and Precautions", and "Description", sections of the labeling were revised in September 2022 to emphasize the appropriate route and site of administration. Vivitrol labeling Xcopri (cenobamate) Psychiatric disorders The "Adverse Reactions" section of the labeling was updated in June 2022 to include psychiatric disorders. Xcopri labeling Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Drug Approval

13 Jun 2024

·www.pharmaceutical-technology.com

FDA approves AstraZeneca’s Farxiga for paediatric T2D patients

Trial results showed a significant decrease in A1C for patients treated with Farxiga versus those given a placebo. Credit: Studio Romantic / Shutterstock. The US Food and Drug Administration (FDA) has granted approval for AstraZeneca ‘s Farxiga (dapagliflozin) for the treatment of paediatric patients aged 10 years and above with type-2 diabetes (T2D) Recommended Buyer's Guides Buyer's Guide Leading Guide to Packaging Materials, Containers and Containment Services for the Pharmaceutical Industry Buyer's Guide Top Guide for Drug Delivery Systems The approval is a significant milestone, expanding the medication’s use to improve glycaemic control in children beyond its previous adult-only indication. The FDA’s decision was based on the randomised, double-blind, placebo-controlled T2NOW Phase III trial. The study assessed the efficacy and safety of dapagliflozin as an additional treatment for children and adolescents already taking metformin, insulin or both. Participants were assigned to receive either dapagliflozin, saxagliptin or a placebo. See Also: Takeda signs option agreement with Ascentage for CML drug UK’s new Netflix-style funding model for antibiotics goes live The trial’s primary goal was to observe the change in A1C (haemoglobin) levels after 26 weeks compared to placebo for both dapagliflozin and saxagliptin. Secondary objectives included monitoring fasting plasma glucose levels and the percentage of patients achieving an A1C level below 7%. Trial results showed a significant decrease in A1C for patients treated with Farxiga versus those given a placebo. The adjusted mean change in A1C was -0.62% for Farxiga compared to +0.41% for the placebo group. Farxiga demonstrated a clinically meaningful improvement in glycaemic control for children and adolescents with T2D. The asset has also been approved for paediatric patients aged 10 years and above with T2D in 56 countries, based on the T2GO Phase III trial. Further regulatory submissions and market evaluations are underway to determine additional rollout plans. In addition to its use in diabetes management, Forxiga is approved in more than 100 countries for treating heart failure across the full ventricular ejection fraction range and chronic kidney disease in adults. AstraZeneca BioPharmaceuticals Business Unit executive vice-president Ruud Dobber stated: “The prevalence of type-2 diabetes continues to rise in children and adolescents, yet oral treatment options have remained limited for this population. “The approval represents an important milestone for paediatric patients living with type-2 diabetes in the US, extending this medicine’s potential benefits to even more patients facing high unmet needs and reinforcing AstraZeneca’s commitment to delivering innovative treatments across cardiovascular, renal and metabolic diseases.” The latest development comes after AstraZeneca‘s supplemental new drug application for Tagrisso obtained FDA priority review for unresectable Stage III epidermal growth factor receptor-mutated non-small cell lung cancer after chemoradiotherapy.

Phase 3Drug ApprovalClinical ResultPriority Review

100 Deals associated with Saxagliptin Hydrate

External Link

KEGG	Wiki	ATC	Drug Bank
D09753 D10262	Saxagliptin Hydrate	A10BH03	DB06335

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Diabetes Mellitus, Type 2	United States	AstraZeneca AB	31 Jul 2009

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Albuminuria	Phase 3	United States	AstraZeneca PLC	21 Sep 2015
Albuminuria	Phase 3	Japan	AstraZeneca PLC	21 Sep 2015
Albuminuria	Phase 3	Australia	AstraZeneca PLC	21 Sep 2015
Albuminuria	Phase 3	Canada	AstraZeneca PLC	21 Sep 2015
Albuminuria	Phase 3	Mexico	AstraZeneca PLC	21 Sep 2015
Albuminuria	Phase 3	South Africa	AstraZeneca PLC	21 Sep 2015
Albuminuria	Phase 3	South Korea	AstraZeneca PLC	21 Sep 2015
Albuminuria	Phase 3	Spain	AstraZeneca PLC	21 Sep 2015
Albuminuria	Phase 3	Taiwan Province	AstraZeneca PLC	21 Sep 2015
Chronic Kidney Diseases	Phase 3	United States	AstraZeneca PLC	21 Sep 2015

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02307695 (Pubmed \| Nutr Diabetes)	Phase 4	Diabetes Mellitus, Type 1	184	Saxagliptin 5 mg + Saxagliptin 5 mg	tupguzoujb(ptvunpjylm): P-Value = 0.04	Positive	02 Mar 2026
				Insulin
NCT02946632 (TRIPLE-AXEL, Pubmed \| Diabetes Obes Metab)	Phase 3	Diabetes Mellitus, Type 2	105	Initial triple combination therapy (TCT)	xurjieoliq(uwzqqtedhq) = dmplsbvyio ffbfrjnpmk (njzsgbfcgw ) View more	Positive	01 Sep 2024
				Stepwise add-on therapy (SAT)	xurjieoliq(uwzqqtedhq) = iymnbplvfg ffbfrjnpmk (njzsgbfcgw ) View more
1340-P (ADA2024)	Not Applicable	Diabetes Mellitus	-	SGLT2i	tntjncaioc(gqmcvmudog) = afxdxzoytl ucdecvhnfg (qbjcucbjww, 16.6 - 19.7)	Positive	14 Jun 2024
				DPP4i	tntjncaioc(gqmcvmudog) = hhayyknpet ucdecvhnfg (qbjcucbjww, 19.1 - 21.4)
NCT02946632 (TRIPLE-AXEL, Pubmed)	-	Diabetes Mellitus, Type 2	105	dapagliflozin +metformin+saxagliptin	euyddfgtqc(hycfajwphh) = ziznxfqruz yizkqnymhw (txeuzedkyy ) View more	Positive	01 Jun 2024
				metformin+glimepiride+sitagliptin	euyddfgtqc(hycfajwphh) = xlbwyqowut yizkqnymhw (txeuzedkyy ) View more
NCT02547935 (DELIGHT, Pubmed \| Cardiovasc Diabetol)	Phase 2/3	Diabetes Mellitus, Type 2 \| Chronic Kidney Diseases hemoglobin \| iron markers \| erythropoietin ... View more	461	Dapagliflozin	ekbugrrroh(xwtkpfafmk) = wwnscziwek jfqgidavfj (kskbnycxmo, 4.0 - 7.3)	Positive	28 Nov 2023
				Dapagliflozin-saxagliptin	ekbugrrroh(xwtkpfafmk) = cysmhutceo jfqgidavfj (kskbnycxmo, 2.7 - 6.0)
NCT04170790 (Pubmed \| Eur J Clin Pharmacol)	Not Applicable	-	18	Saxagliptin 5 mg	apmkxfnoee(nwhabjgpgg): T/R = 132.1 (90% CI, 122.7 - 142.3) View more	-	10 Oct 2022
				Sildenafil 50 mg
NCT02917031 (MEASURE-HF, CTgov)	Phase 4	Diabetes Mellitus, Type 2 \| Heart Failure \| Heart failure with reduced ejection fraction	348	Placebo to match sitagliptin+Saxagliptin (Saxagliptin)	gatbemykmj(ojhvbhtmfw) = wxtlncgdpe zyxwyjllsn (speeeitjtt, 15.3412) View more	-	18 Jun 2021
				Placebo to match saxagliptin (Placebo)	gatbemykmj(ojhvbhtmfw) = caffrweyny zyxwyjllsn (speeeitjtt, 18.1178) View more
NCT02597101 (CTgov)	Phase 2	Diabetes Mellitus, Type 2 \| Insulin Resistance \| Obesity	14	placebo+Metformin+saxagliptin (Placebo)	xemponvaee(jwuydtddre) = ydxpslucim nzsdhtzwia (qhmkwrisje, 3.7) View more	-	13 May 2021
				AZD9668+Metformin+saxagliptin (AZD9668)	xemponvaee(jwuydtddre) = zxpxtdwlmu nzsdhtzwia (qhmkwrisje, 3.5) View more
NCT02419612 (Pubmed \| Diabetes Obes Metab) Manual	Phase 3	Diabetes Mellitus, Type 2	444	dapagliflozin + saxagliptin	lwifkyfpjr(mdijsvmnql) = hqazbghnru uxrsollymj (ydajdvsrim ) View more	Superior	01 Jul 2020
				glimepiride	lwifkyfpjr(mdijsvmnql) = qmyceyckjd uxrsollymj (ydajdvsrim ) View more
NCT01548651 (CTgov)	Phase 4	Glucose Intolerance \| Inflammation	8	Placebo (Placebo)	jsbuorlels(vtttctqnvj) = bnzqxyhhak aaankuapxz (vujvmmroap, wdqmmkwptk - sfmdxbevdu) View more	-	13 Jan 2020
				Saxagliptin (Saxagliptin)	jsbuorlels(vtttctqnvj) = aabylphmdc aaankuapxz (vujvmmroap, dlbldnmlgy - nhthpqznwq) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis